Alto Neuroscience (ANRO) Receivables - Other (2023 - 2024)
Alto Neuroscience (ANRO) reported Receivables - Other of -$8000.0 for Q1 2024, down 121.62% on a YoY basis from $37000.0 in Q2 2023, and down 200.0% sequentially from $8000.0 in Q4 2023.
Alto Neuroscience (ANRO) Receivables - Other (2023 - 2024) Analysis & Trends
Alto Neuroscience (ANRO) has 2 years of Receivables - Other data on file, last reported at -$8000.0 in Q1 2024.
- For the quarter ending Q1 2024, Receivables - Other fell 121.62% year-over-year to -$8000.0; the trailing twelve-month figure through Mar 2024 stood at -$333000.0 (changed N/A YoY), and the FY2023 full-year result was $8000.0, changed N/A from the prior year.
- Receivables - Other eased to -$8000.0 in Q1 2024, from $8000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $37000.0 in Q1 2023 to a low of -$295000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alto Neuroscience | 881.86 Mn | 881.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -8,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Dec 31, 2023 | 8,000.00 |
| Dec 31, 2023 | 8,000.00 |
| Sep 30, 2023 | -295,000.00 |
| Sep 30, 2023 | -295,000.00 |
| Jun 30, 2023 | -67,000.00 |
| Jun 30, 2023 | -67,000.00 |
| Mar 31, 2023 | 37,000.00 |
| Mar 31, 2023 | 37,000.00 |